I suggest you to read the latest 10-Q. It’ll tel
Post# of 72440
Dilutions are part of the game for early biotechs. If the company is acquired, the SP will be based on fully diluted shares anyway.
You seem to ignore the possibility of a partnership for either Prurisol or Kevetrin in 2016. Why so pessimistic?